Login
$AQST
$4.07 +$0.00 (0.0%) After hours

Company Executives

$AQST Management Team

Ms. Sherry Korczynski

Chief Commercial Officer

Age 55
Compensation -
Sex Female

Mr. Daniel Barber

President

Chief Executive Officer

Director

Age 49
Compensation $4.181M USD
Sex Male

Mr. John Cochran

Independent Vice Chairman of the Board

Age 59
Compensation $156.6K USD
Sex Male

Mr. A. Ernest Toth

Chief Financial Officer

Age 66
Compensation $1.116M USD
Sex Male

Ms. Cassie Jung

Chief Operating Officer

Age 46
Compensation -
Sex Female

Ms. Lori Braender

Chief Legal Officer

Chief Compliance Officer and Corporate Secretary

Age 69
Compensation $1.821M USD
Sex Female

Ms. Stephanie Carrington

Investor Relations

Age -
Compensation -
Sex Female

Dr. Gregory Brown

Independent Chairman of the Board

Age 72
Compensation $198.5K USD
Sex Male

Dr. Melina Cioffi

Senior Vice President - Regulatory Affairs

Age 42
Compensation -
Sex Female

Mr. Peter Boyd

Chief People Officer

Age 59
Compensation -
Sex Male

Dr. Matthew Greenhawt

Chief Medical Officer

Age -
Compensation -
Sex Male
Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
8.7 years
from year joined
CEO also chairs the board
No
Gregory B. Brown, M.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Gregory B. Brown, M.D.
Not stated 2007
19 years
Independent None stated Lisata Therapeutics, Inc. $274,641
John S. Cochran
Not stated 2004
22 years
Independent None stated None stated $240,919
Abigail L. Jenkins
Not stated 2024
2 years
Independent None stated None stated $200,917
Julie Krop, M.D.
Not stated 2021
5 years
Independent None stated None stated $233,220
Marco Taglietti, M.D.
Not stated 2021
5 years
Independent None stated None stated $213,412
Daniel Barber
Not stated 2022
4 years
Not independent None stated None stated Paid as CEO
Timothy E. Morris
Not stated 2022
4 years
Independent None stated DBV Technologies $237,612

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

5 disclosed in the proxy filed Apr 24, 2026
Daniel Barber
registration rights holder under his employment agreement
Amount not stated

Registration rights granted to Mr. Barber pursuant to his employment agreement; shares registered for resale on Form S-3 filings dated September 11, 2019 and January 8, 2021.

MRX Partners LLC, Monoline RX L.P., Monoline Rx II, L.P., Monoline Rx III, L.P., Monoline Rx Genpar, MonoSol Investors L.P., Douglas K. Bratton, Peter Boyd, Lori Braender, Gregory B. Brown, M.D. and John S. Cochran
holders granted registration rights
Amount not stated

Registration rights granted to these related parties, with pro rata reduction provisions on inclusion in future registered offerings.

each of our directors and executive officers
director or executive officer
Amount not stated

Indemnification agreements providing contractual rights to indemnification and expense advancement.

Daniel Barber
participant in Capital Funding Transaction
Amount not stated
June 8, 2022

Purchased 91,743 shares of common stock at $1.09 per share and received a warrant for the same number of shares at $0.96 per share in the June 2022 capital funding program.

Lori Braender
participant in Capital Funding Transaction
Amount not stated
June 8, 2022

Purchased 13,761 shares of common stock at $1.09 per share and received a warrant for the same number of shares at $0.96 per share in the June 2022 capital funding program.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support